270 related articles for article (PubMed ID: 26884583)
1. Bispecific T-Cell Engagers (BiTEs) as Treatment of B-Cell Lymphoma.
Smits NC; Sentman CL
J Clin Oncol; 2016 Apr; 34(10):1131-3. PubMed ID: 26884583
[No Abstract] [Full Text] [Related]
2. Bispecific T-Cell Engager (BiTE) Antibody Construct Blinatumomab for the Treatment of Patients With Relapsed/Refractory Non-Hodgkin Lymphoma: Final Results From a Phase I Study.
Goebeler ME; Knop S; Viardot A; Kufer P; Topp MS; Einsele H; Noppeney R; Hess G; Kallert S; Mackensen A; Rupertus K; Kanz L; Libicher M; Nagorsen D; Zugmaier G; Klinger M; Wolf A; Dorsch B; Quednau BD; Schmidt M; Scheele J; Baeuerle PA; Leo E; Bargou RC
J Clin Oncol; 2016 Apr; 34(10):1104-11. PubMed ID: 26884582
[TBL] [Abstract][Full Text] [Related]
3. Unleashing the clinical power of T cells: CD19/CD3 bi-specific T cell engager (BiTE®) antibody construct blinatumomab as a potential therapy.
Zimmerman Z; Maniar T; Nagorsen D
Int Immunol; 2015 Jan; 27(1):31-7. PubMed ID: 25239133
[TBL] [Abstract][Full Text] [Related]
4. Blinatumomab: a novel agent to treat minimal residual disease in patients with acute lymphoblastic leukemia.
Advani AS
Clin Adv Hematol Oncol; 2011 Oct; 9(10):776-7. PubMed ID: 22252580
[No Abstract] [Full Text] [Related]
5. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma.
Viardot A; Goebeler ME; Hess G; Neumann S; Pfreundschuh M; Adrian N; Zettl F; Libicher M; Sayehli C; Stieglmaier J; Zhang A; Nagorsen D; Bargou RC
Blood; 2016 Mar; 127(11):1410-6. PubMed ID: 26755709
[TBL] [Abstract][Full Text] [Related]
6. Potential for bispecific T-cell engagers: role of blinatumomab in acute lymphoblastic leukemia.
Le Jeune C; Thomas X
Drug Des Devel Ther; 2016; 10():757-65. PubMed ID: 26937176
[TBL] [Abstract][Full Text] [Related]
7. Functionally Defective T Cells After Chemotherapy of B-Cell Malignancies Can Be Activated by the Tetravalent Bispecific CD19/CD3 Antibody AFM11.
Duell J; Lukic DS; Karg M; Reusch U; Koch J; Zhukovsky EA; Rajkovic E; Treder M; Rasche L; Eisele F; Einsele H; Topp MS
J Immunother; 2019 Jun; 42(5):180-188. PubMed ID: 31090657
[TBL] [Abstract][Full Text] [Related]
8. Current and future role of bispecific T-cell engagers in pediatric acute lymphoblastic leukemia.
Algeri M; Del Bufalo F; Galaverna F; Locatelli F
Expert Rev Hematol; 2018 Dec; 11(12):945-956. PubMed ID: 30358451
[TBL] [Abstract][Full Text] [Related]
9. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.
Bargou R; Leo E; Zugmaier G; Klinger M; Goebeler M; Knop S; Noppeney R; Viardot A; Hess G; Schuler M; Einsele H; Brandl C; Wolf A; Kirchinger P; Klappers P; Schmidt M; Riethmüller G; Reinhardt C; Baeuerle PA; Kufer P
Science; 2008 Aug; 321(5891):974-7. PubMed ID: 18703743
[TBL] [Abstract][Full Text] [Related]
10. Efficient elimination of chronic lymphocytic leukaemia B cells by autologous T cells with a bispecific anti-CD19/anti-CD3 single-chain antibody construct.
Löffler A; Gruen M; Wuchter C; Schriever F; Kufer P; Dreier T; Hanakam F; Baeuerle PA; Bommert K; Karawajew L; Dörken B; Bargou RC
Leukemia; 2003 May; 17(5):900-9. PubMed ID: 12750704
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
[TBL] [Abstract][Full Text] [Related]
12. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. II. Assessment of cellular immune responses.
Manzke O; Tesch H; Lorenzen J; Diehl V; Bohlen H
Int J Cancer; 2001 Feb; 91(4):516-22. PubMed ID: 11251975
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
Ribera JM
Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
[TBL] [Abstract][Full Text] [Related]
14. Clinical experience with CD3 x CD19 bispecific antibodies in patients with B cell malignancies.
De Gast GC; Van Houten AA; Haagen IA; Klein S; De Weger RA; Van Dijk A; Phillips J; Clark M; Bast BJ
J Hematother; 1995 Oct; 4(5):433-7. PubMed ID: 8581381
[TBL] [Abstract][Full Text] [Related]
15. Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab.
Klinger M; Brandl C; Zugmaier G; Hijazi Y; Bargou RC; Topp MS; Gökbuget N; Neumann S; Goebeler M; Viardot A; Stelljes M; Brüggemann M; Hoelzer D; Degenhard E; Nagorsen D; Baeuerle PA; Wolf A; Kufer P
Blood; 2012 Jun; 119(26):6226-33. PubMed ID: 22592608
[TBL] [Abstract][Full Text] [Related]
16. Locoregional treatment of low-grade B-cell lymphoma with CD3xCD19 bispecific antibodies and CD28 costimulation. I. Clinical phase I evaluation.
Manzke O; Tesch H; Borchmann P; Wolf J; Lackner K; Gossmann A; Diehl V; Bohlen H
Int J Cancer; 2001 Feb; 91(4):508-15. PubMed ID: 11251974
[TBL] [Abstract][Full Text] [Related]
17. Chimeric antigen receptor T-cell immunotherapy tackles blood cancers.
Brower V
J Natl Cancer Inst; 2015 Apr; 107(4):. PubMed ID: 25838441
[No Abstract] [Full Text] [Related]
18. Immunotherapy of B-cell non-Hodgkin lymphoma by targeting the chemokine receptor CXCR5 in a preclinical mouse model.
Panjideh H; Müller G; Koch M; Wilde F; Scheu S; Moldenhauer G; Lipp M
Int J Cancer; 2014 Dec; 135(11):2623-32. PubMed ID: 24729415
[TBL] [Abstract][Full Text] [Related]
19. Blinatumomab: a CD19/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy.
Goebeler ME; Bargou R
Leuk Lymphoma; 2016 May; 57(5):1021-32. PubMed ID: 27050240
[TBL] [Abstract][Full Text] [Related]
20. MGD011, A CD19 x CD3 Dual-Affinity Retargeting Bi-specific Molecule Incorporating Extended Circulating Half-life for the Treatment of B-Cell Malignancies.
Liu L; Lam CK; Long V; Widjaja L; Yang Y; Li H; Jin L; Burke S; Gorlatov S; Brown J; Alderson R; Lewis MD; Nordstrom JL; Koenig S; Moore PA; Johnson S; Bonvini E
Clin Cancer Res; 2017 Mar; 23(6):1506-1518. PubMed ID: 27663593
[No Abstract] [Full Text] [Related]
[Next] [New Search]
